Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2015, Article ID 835985, 19 pages
Review Article

PPARs: Protectors or Opponents of Myocardial Function?

Temple University School of Medicine, Department of Pharmacology, Center for Translational Medicine, Philadelphia, PA 19140, USA

Received 31 July 2015; Revised 5 November 2015; Accepted 8 November 2015

Academic Editor: Nanping Wang

Copyright © 2015 Christine J. Pol et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Over 5 million people in the United States suffer from the complications of heart failure (HF), which is a rapidly expanding health complication. Disorders that contribute to HF include ischemic cardiac disease, cardiomyopathies, and hypertension. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor family. There are three PPAR isoforms: PPARα, PPARγ, and PPARδ. They can be activated by endogenous ligands, such as fatty acids, as well as by pharmacologic agents. Activators of PPARs are used for treating several metabolic complications, such as diabetes and hyperlipidemia that are directly or indirectly associated with HF. However, some of these drugs have adverse effects that compromise cardiac function. This review article aims to summarize the current basic and clinical research findings of the beneficial or detrimental effects of PPAR biology on myocardial function.